Immix Biopharma (IMMX) Cash & Equivalents (2020 - 2026)

Immix Biopharma has reported Cash & Equivalents for 7 years, with the latest figure at $79.3 million in Q1 2026.

• Quarterly Cash & Equivalents rose 397.77% year-over-year to $79.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $79.3 million (up 397.77% YoY) and the FY2025 annual result came in at $93.9 million, up 431.21% from the prior year.
• Cash & Equivalents fell to $79.3 million in Q1 2026 per IMMX's latest filing, from $93.9 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $93.9 million in Q4 2025 and troughed at $11.5 million in Q1 2023.
• A 5-year average of $25.7 million and a median of $17.7 million in 2024 frame the typical range for Cash & Equivalents.
• The widest YoY moves for Cash & Equivalents: up 431.21% in 2025, down 51.62% in 2025.
• Over 5 years, Cash & Equivalents stood at $13.4 million in 2022, then surged by 30.31% to $17.5 million in 2023, then rose by 0.98% to $17.7 million in 2024, then jumped by 431.21% to $93.9 million in 2025, then declined by 15.63% to $79.3 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $79.3 million, $93.9 million, and $15.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.